



## ASX Release

EMvision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

### ADVANCE QLD INDUSTRY FELLOWSHIP WIN

**EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”)**, a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to advise that, in a collaboration with the University of Queensland (UQ), Keysight Technologies (NYSE:KEYS) and Metro South Hospital & Health Service (PA Hospital), a key member of the UQ electromagnetic imaging algorithm team has won a prestigious Advance QLD Industry Research Fellowship.

This Fellowship includes a total of \$180,000, over 3 years, in Advance QLD funding towards their role in EMVision’s technology development program. The Fellow will be physically co-located between UQ (applicant), EMVision (partner) and Metro South Health (partner). Keysight Technologies will provide in-kind contribution in the form of technical and implementation expertise. This Fellow will add further capacity to EMVision’s R&D and artificial intelligence driven electromagnetic imaging capabilities. The funding agreement for this fellowship is anticipated to be executed shortly.

EMVision’s CEO, Dr Ron Weinberger, commented “The Advance Queensland Fellowship is a highly competitive process to support outstanding research projects and individuals. This recognizes the quality of research of Professor Abbosh’s team at the University of Queensland and the collaboration of its industry partners. The support of Keysight is very much appreciated and is ongoing evidence of our strong partnership and substantial progress that has been made in our project”

Authorised for release by the Board of the Company.

**[ENDS]**

For further information, media or investor enquiries, please contact:

Michael Wills  
Investor & Media Relations  
+61 468 385 208  
michael@spring-communications.com.au

Scott Kirkland  
Executive Director  
+61 2 8667 5337  
skirkland@emvision.com.au

#### About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision’s CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics’ (ASX:NAN), a \$2 billion market cap healthcare company. Dr Weinberger has over 25-years’ experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company’s platform technology and launched their breakthrough product ‘Trophon’ globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in

transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

### **About Advance Queensland Industry Research Fellowships**

The Queensland Government established the Advance Queensland Industry Research Fellowships program to provide funding assistance to outstanding early and mid-career researchers to undertake research at a Queensland-based agency that will benefit Queensland. The program assists in attracting and keeping the best and brightest research minds in Queensland, and builds Queensland's capacity to conduct innovative research and development in partnership with industry.

### **Forward-looking Statements**

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.